63
50. Lima MA, Harab RC, Schor D, Andrada-Serpa MJ, Araujo AQ. Subacute
progression of human T-lymphotropic virus type I-associated myelopathy/tropical spastic
paraparesis. J Neurovirol. 2007 Oct;13(5):468-73.
51. Kaplan JE, Osame M, Kubota H, Igata A, Nishitani H, Maeda Y, et al. The risk of
development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons
infected with HTLV-I. J Acquir Immune Defic Syndr. 1990;3(11):1096-101.
52. Izumo S, Goto I, Itoyama Y, Okajima T, Watanabe S, Kuroda Y, et al. Interferon-
alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-
blind, controlled trial. Neurology. 1996 Apr;46(4):1016-21.
53. Castro-Costa CM, Dom R, Carton H, Goubau P, Santos Tde J, Ferreira MV, et al.
Neuropathology of two Brazilian autopsied cases of tropical spastic paraparesis / HTLV-I
associated myelopathy (TSP/HAM) of long evolution. Arq Neuropsiquiatr. 2002 Sep;60(3-
A):531-6.
54. Castro-Costa CM, Carton H, Santos TJ. HTLV-I negative tropical spastic
paraparesis: a scientific challenge. Arq Neuropsiquiatr. 2001 Jun;59(2-A):289-94.
55. Osame M, Igata A, Matsumoto M. HTLV-1-associated myelopathy (HAM)
revisited. In: Román G, Vernant J, Osame M, editors. HTLV-1 and the Nervous System.
New York: Alan R Liss; 1989. p. 213-23.
56. Araujo A, Lima MA, Silva MT. Human T-lymphotropic virus 1 neurologic disease.
Curr Treat Options Neurol. 2008 May;10(3):193-200.
57. Araujo AQ, Afonso CR, Leite AC, Dultra SV. Intravenous methylprednisolone in
HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). Arq
Neuropsiquiatr. 1993 Sep;51(3):325-8.
58. Ijichi S, Ijichi N, Osame M, Izumihara T, Niimura T. [Efficacy of
leukocytapheresis and low-dose prednisolone treatment in a patient with HTLV-I-
associated myelopathy (HAM)]. Rinsho Shinkeigaku. 1990 May;30(5):544-7.
59. Yamasaki K, Kira J, Koyanagi Y, Kawano Y, Miyano-Kurosaki N, Nakamura M, et
al. Long-term, high dose interferon-alpha treatment in HTLV-I-associated
myelopathy/tropical spastic paraparesis: a combined clinical, virological and
immunological study. J Neurol Sci. 1997 Apr 15;147(2):135-44.
60. Kuroda Y, Kurohara K, Fujiyama F, Takashima H, Endo C, Matsui M, et al.
Systemic interferon-alpha in the treatment of HTLV-I-associated myelopathy. Acta Neurol
Scand. 1992 Jul;86(1):82-6.